15 Feb 2024 • In a nationwide study, researchers investigated the optimal oral antidiabetic drug class for individuals with NAFLD and type 2 diabetes.

Compared to thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sulfonylureas, SGLT2 inhibitors exhibited a significantly higher likelihood of NAFLD regression.

Moreover, they were the sole class associated with lower incidences of adverse liver-related outcomes.

The results of this cohort study suggest that physicians may lean towards prescribing SGLT2 inhibitors as the preferred OAD for individuals with NAFLD and T2D, considering their potential benefits in NAFLD regression and lower incidences of adverse liver-related outcomes.

Source: JAMA | Read full story